Arash Keshavarzi

AI at @stanford, investor @Mubadala Capital, xCSO @NucleusGenomics. Ph.D.

Recently built for finance

[Thore @buergelt_]

1/ Two weeks ago we published our first predictions on upcoming clinical readouts.

Today we're adding five more.

[Arash Keshavarzi @arashka20]

If you are building in verticals, lets chat!
I think the biggest opportunity in today's AI is in verticals, especially healthcare and finance. That's where you can build monopoly and avoid competition.

The best scenario imo is to build both platform and model infra

[Arash Keshavarzi @arashka20]

Mute the noise. Chase the sharpest problem. Ship, learn, fix, repeat until they love it. Stop taking advice from investors who’ve never fought a round.

[Icons @sv_icons]

SV Icons' dinner with @htaneja is the one to remember. Hemant is the CEO of @generalcatalyst and has invested in companies that have transformed industries forever.

The three lessons he shared that none of us will forget include:

1) Pattern recognition can kill innovation - Every new venture unfolds in a different market, with shifting tech and unpredictable users. Relying on pattern recognition can blind us to the fresh possibilities each company holds.

Always remember to stay curious.

2) Collaboration can change the world - Innovation doesn’t happen in isolation. It happens within teams, across organizations, and among ecosystems.

When we welcome diverse perspectives, we unlock potential that can't be achieved alone.

3) Always keep an entrepreneurial mindset - staying entrepreneurial means constantly questioning assumptions, taking calculated risks, and iterating with speed. It's the only correct mindset for transformative growth, especially in times of uncertainty.

This dinner represents what Icons truly stands for -
giving the next wave of founders the unfair advantage of having real talks with the brightest minds in the industry.

Lots of laughs too.😁

[Arash Keshavarzi @arashka20]

The recipe:

Focus, speed, iteration

[Arash Keshavarzi @arashka20]

Best I've heard in a while!
Ep 112: Peter Thiel on DOGE, Tariffs, Building Generational Companies & the Future of Civilization, by @JTLonsdale https://t.co/yiQueOTbol

[Arash Keshavarzi @arashka20]

Had a great time with Stanford’s Icon and @chadbyers , co founder of @SusaVentures . Thank you @simbajonga2

[Simba 🇺🇸 @simbajonga2]

Had the privilege of hosting @ChadByers, Co-Founder @SusaVentures, for an @sv_icons dinner. Chad is a first principles and first-rate thinker—one of the sharpest investors I’ve ever met.

We had an off-the-record conversation about what makes great founders like @typesfast at @flexport, the artistry of seed investing being all about the founder, untapped opportunities in older industries, scaling ambition and hard work, why Silicon Valley is so unique, and how next-gen AI application could replace (not just augment) knowledge workers.

Grateful for Chad’s humility and brilliant insights!

[sid 🌱 @notcodesid]

a quick reminder for every day.

[Arash Keshavarzi @arashka20]

@JoshConstine Done

[Arash Keshavarzi @arashka20]

Finding talent is f tricky! I’d go with the ones who are not experts but are willing to learn/try whatever

[Arash Keshavarzi @arashka20]

Thank you @ycombinator for having us

[Arash Keshavarzi @arashka20]

if you believe in remote work, you probably should not build an start up!

[Arc Institute @arcinstitute]

🧬 Turns out, mRNA isn't just a passive genetic courier.
Arc’s Goodarzi lab, in collaboration with @LukeGilbertSF’s lab, discovered that mRNA can actively control its own expression using newly discovered "RNA switches." The team found over 200 of these switches in human cells, previously thought to exist only in simple, single-celled organisms.

This has the potential to help revolutionize drug development, especially for "undruggable" proteins that can’t be targeted by therapeutics directly.

Congrats to Arc Core Investigator and UCSF Associate Professor of Biochemistry and Biophysics @genophoria, Arc Post Doc @khorms57 and the entire team on this exciting work.

Read the study in Nature Methods: https://t.co/xjLYwYLENR and learn more in @khorms57 ‘Behind the paper’ blog post: https://t.co/Iy5dPudf58
Check out the Goodarzi lab’s SwitchFinder tool designed for the systematic discovery of RNA structural switches within transcriptomes: https://t.co/6G3Qcd4EMN

[Arash Keshavarzi @arashka20]

I’ve made $30,303,932 playing the @business Trading Game. Can you beat the market? Play now: https://t.co/1YXXQU6AQO

[Arash Keshavarzi @arashka20]

This is a great opportunity for anyone interested in building a biotech company! @kulesatony @pillar_vc

[Tony Kulesa @kulesatony]

Frequency is back for Summer 2024. Apply by July 2!

If you are interested in starting biotech companies, this is a 1 week, part time, crash course experience in all aspects of early stage company building.

Alumni have started leading companies + joined top VC firms worldwide.

[Tony Kulesa @kulesatony]

Frequency is back for Summer 2024. Apply by July 2!

If you are interested in starting biotech companies, this is a 1 week, part time, crash course experience in all aspects of early stage company building.

Alumni have started leading companies + joined top VC firms worldwide.

[Arash Keshavarzi @arashka20]

@genophoria @arcinstitute Congrats!

[Patrick Hsu @pdhsu]

RNAs have been historically very challenging to drug. @arcinstitute and @ucsf investigator Hani Goodarzi @genophoria reports an AI framework for targeting microRNAs with small molecules (with implications for breast cancer and RNA drivers of other diseases)

Arc loves AI and RNA!

[Arash Keshavarzi @arashka20]

5 years of hard work is finally out!

[Eric Topol @EricTopol]

How do you go from 9 million molecules to 8 which appear effective against a micro RNA driver of breast cancer?
Like this
https://t.co/6rqOcH0WDK @Patterns_CP #AI @genophoria @UCSF @UCSFCancer

[Bruna Gomes @BGomes_1905]

Thrilled to announce our latest publication in Nature Genetics today, dissecting the genetics of cardiac flow volumes.
https://t.co/zaJhWnI1gR